表皮生长因子受体突变 NSCLC 中同时出现 HER2 突变：病例报告

IF 3 Q2 ONCOLOGY

JTO Clinical and Research Reports Pub Date : 2024-09-07 DOI:10.1016/j.jtocrr.2024.100719

Blerina Resuli MD , Diego Kauffmann-Guerrero MD , Jürgen Behr MD , Amanda Tufman MD

{"title":"表皮生长因子受体突变 NSCLC 中同时出现 HER2 突变：病例报告","authors":"Blerina Resuli MD , Diego Kauffmann-Guerrero MD , Jürgen Behr MD , Amanda Tufman MD","doi":"10.1016/j.jtocrr.2024.100719","DOIUrl":null,"url":null,"abstract":"<div><div><em>HER2</em> mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of <em>HER2</em> and <em>EGFR</em> mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100719"},"PeriodicalIF":3.0000,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports\",\"authors\":\"Blerina Resuli MD , Diego Kauffmann-Guerrero MD , Jürgen Behr MD , Amanda Tufman MD\",\"doi\":\"10.1016/j.jtocrr.2024.100719\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div><em>HER2</em> mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of <em>HER2</em> and <em>EGFR</em> mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.</div></div>\",\"PeriodicalId\":17675,\"journal\":{\"name\":\"JTO Clinical and Research Reports\",\"volume\":\"5 12\",\"pages\":\"Article 100719\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-09-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JTO Clinical and Research Reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666364324000894\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000894","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

HER2 基因突变和扩增已被确定为肺癌中不同的分子靶点，具有不同的治疗和预后价值。HER2 和表皮生长因子受体（EGFR）突变同时存在的情况极为罕见，因此目前还没有关于这些病例最佳治疗方法的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports

HER2 mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of HER2 and EGFR mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

JTO Clinical and Research Reports Medicine-Oncology

CiteScore

4.20

自引率

0.00%

发文量

145

审稿时长

19 weeks